Does the media favor BMRN or NTRA?

In the previous week, Natera had 10 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 40 mentions for Natera and 30 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 1.33 beat Natera's score of 1.30 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 21 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Natera 30 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor BMRN or RVMD?

In the previous week, Revolution Medicines had 53 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 83 mentions for Revolution Medicines and 30 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 1.33 beat Revolution Medicines' score of 0.84 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 21 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 42 Very Positive mention(s) 11 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 5 Very Negative mention(s) Positive

Does the media prefer BIIB or BMRN?

In the previous week, Biogen had 5 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 35 mentions for Biogen and 30 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 1.33 beat Biogen's score of 1.23 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 30 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 21 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BMRN or ALNY?

In the previous week, BioMarin Pharmaceutical and BioMarin Pharmaceutical both had 30 articles in the media. BioMarin Pharmaceutical's average media sentiment score of 1.33 beat Alnylam Pharmaceuticals' score of 1.07 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 21 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 21 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BMRN or BNTX?

In the previous week, BioMarin Pharmaceutical had 8 more articles in the media than BioNTech. MarketBeat recorded 30 mentions for BioMarin Pharmaceutical and 22 mentions for BioNTech. BioMarin Pharmaceutical's average media sentiment score of 1.33 beat BioNTech's score of -0.04 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 21 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 6 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 4 Very Negative mention(s) Neutral

BioMarin Pharmaceutical (BMRN) Competitors

$65.57 +0.90 (+1.39%)

As of 03:45 PM Eastern

Compare

BMRN vs. NTRA, RVMD, BIIB, ALNY, and BNTX

Should you buy BioMarin Pharmaceutical stock or one of its competitors? BioMarin Pharmaceutical's main competitors and comparable companies include Natera (NTRA), Revolution Medicines (RVMD), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), and BioNTech (BNTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioMarin Pharmaceutical compare to Natera?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

BioMarin Pharmaceutical has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.94	$348.90M	$0.37	177.22
Natera	$2.71B	17.01	-$208.16M	-$1.36	N/A

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 0.7% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 5.1% of Natera shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Natera had 10 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 40 mentions for Natera and 30 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 1.33 beat Natera's score of 1.30 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	21 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Natera	30 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

BioMarin Pharmaceutical presently has a consensus price target of $88.92, suggesting a potential upside of 35.61%. Natera has a consensus price target of $319.38, suggesting a potential downside of 0.05%. Given BioMarin Pharmaceutical's higher probable upside, equities analysts plainly believe BioMarin Pharmaceutical is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.75
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82

BioMarin Pharmaceutical has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Natera has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Natera's net margin of -7.11%. BioMarin Pharmaceutical's return on equity of 5.32% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Natera	-7.11%	-11.38%	-7.87%

Summary

BioMarin Pharmaceutical beats Natera on 9 of the 15 factors compared between the two stocks.

How does BioMarin Pharmaceutical compare to Revolution Medicines?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

BioMarin Pharmaceutical presently has a consensus price target of $88.92, indicating a potential upside of 35.61%. Revolution Medicines has a consensus price target of $200.74, indicating a potential downside of 1.79%. Given BioMarin Pharmaceutical's higher probable upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.75
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

BioMarin Pharmaceutical has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.94	$348.90M	$0.37	177.22
Revolution Medicines	$11.58M	3,783.16	-$1.13B	-$8.82	N/A

BioMarin Pharmaceutical has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market.

In the previous week, Revolution Medicines had 53 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 83 mentions for Revolution Medicines and 30 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 1.33 beat Revolution Medicines' score of 0.84 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	21 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	42 Very Positive mention(s)	11 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	5 Very Negative mention(s)	Positive

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 0.7% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 7.6% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Revolution Medicines' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Revolution Medicines	N/A	-88.20%	-57.85%

Summary

BioMarin Pharmaceutical beats Revolution Medicines on 10 of the 16 factors compared between the two stocks.

How does BioMarin Pharmaceutical compare to Biogen?

Biogen (NASDAQ:BIIB) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Biogen currently has a consensus price target of $227.79, indicating a potential upside of 4.73%. BioMarin Pharmaceutical has a consensus price target of $88.92, indicating a potential upside of 35.61%. Given BioMarin Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.75

Biogen has higher revenue and earnings than BioMarin Pharmaceutical. Biogen is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.25	$1.29B	$5.65	38.50
BioMarin Pharmaceutical	$3.22B	3.94	$348.90M	$0.37	177.22

In the previous week, Biogen had 5 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 35 mentions for Biogen and 30 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 1.33 beat Biogen's score of 1.23 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	30 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	21 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

87.9% of Biogen shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 0.3% of Biogen shares are owned by insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Biogen has a net margin of 8.32% compared to BioMarin Pharmaceutical's net margin of 2.14%. Biogen's return on equity of 11.18% beat BioMarin Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

Biogen has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

Summary

BioMarin Pharmaceutical beats Biogen on 9 of the 17 factors compared between the two stocks.

How does BioMarin Pharmaceutical compare to Alnylam Pharmaceuticals?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

BioMarin Pharmaceutical has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.94	$348.90M	$0.37	177.22
Alnylam Pharmaceuticals	$3.71B	8.66	$313.75M	$5.38	44.70

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to BioMarin Pharmaceutical's net margin of 2.14%. Alnylam Pharmaceuticals' return on equity of 84.93% beat BioMarin Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

BioMarin Pharmaceutical presently has a consensus price target of $88.92, suggesting a potential upside of 35.61%. Alnylam Pharmaceuticals has a consensus price target of $386.14, suggesting a potential upside of 60.58%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.75
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.88

BioMarin Pharmaceutical has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market.

In the previous week, BioMarin Pharmaceutical and BioMarin Pharmaceutical both had 30 articles in the media. BioMarin Pharmaceutical's average media sentiment score of 1.33 beat Alnylam Pharmaceuticals' score of 1.07 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	21 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	21 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alnylam Pharmaceuticals beats BioMarin Pharmaceutical on 11 of the 15 factors compared between the two stocks.

How does BioMarin Pharmaceutical compare to BioNTech?

BioMarin Pharmaceutical (NASDAQ:BMRN) and BioNTech (NASDAQ:BNTX) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

BioMarin Pharmaceutical has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.94	$348.90M	$0.37	177.22
BioNTech	$3.25B	7.88	-$1.29B	-$7.83	N/A

BioMarin Pharmaceutical has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market.

BioMarin Pharmaceutical has a net margin of 2.14% compared to BioNTech's net margin of -63.54%. BioMarin Pharmaceutical's return on equity of 5.32% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
BioNTech	-63.54%	-6.86%	-6.00%

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 0.7% of BioMarin Pharmaceutical shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, BioMarin Pharmaceutical had 8 more articles in the media than BioNTech. MarketBeat recorded 30 mentions for BioMarin Pharmaceutical and 22 mentions for BioNTech. BioMarin Pharmaceutical's average media sentiment score of 1.33 beat BioNTech's score of -0.04 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	21 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	6 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	4 Very Negative mention(s)	Neutral

BioMarin Pharmaceutical presently has a consensus target price of $88.92, suggesting a potential upside of 35.61%. BioNTech has a consensus target price of $127.44, suggesting a potential upside of 26.04%. Given BioMarin Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.75
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

Summary

BioMarin Pharmaceutical beats BioNTech on 13 of the 17 factors compared between the two stocks.

Get BioMarin Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMRN vs. The Competition

Export

Metric	BioMarin Pharmaceutical	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.69B	$3.92B	$7.13B	$12.83B
Dividend Yield	N/A	3.61%	2.54%	11.27%
P/E Ratio	177.22	11.86	272.92	25.51
Price / Sales	3.94	1,395.48	686.04	122.84
Price / Cash	22.66	44.06	28.74	36.03
Price / Book	2.07	16.80	11.05	6.33
Net Income	$348.90M	-$22.71M	$3.47B	$349.45M
7 Day Performance	0.77%	2.79%	1.24%	-0.09%
1 Month Performance	9.25%	12.98%	8.25%	4.37%
1 Year Performance	12.53%	54.58%	24.13%	14.79%

BioMarin Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMRN BioMarin Pharmaceutical	4.8996 of 5 stars	$65.57 +1.4%	$88.92 +35.6%	+11.0%	$12.69B	$3.22B	177.22	3,221	Positive News Analyst Forecast
NTRA Natera	2.7036 of 5 stars	$327.82 +0.9%	$319.38 -2.6%	+93.9%	$47.25B	$2.31B	N/A	6,140	Positive News Insider Trade
RVMD Revolution Medicines	2.5052 of 5 stars	$209.19 -1.2%	$167.89 -19.7%	+447.5%	$44.84B	N/A	N/A	250	Analyst Forecast Analyst Revision
BIIB Biogen	3.6243 of 5 stars	$218.24 +1.8%	$227.07 +4.0%	+65.3%	$32.24B	$9.89B	38.63	7,500	Positive News
ALNY Alnylam Pharmaceuticals	4.6157 of 5 stars	$238.43 +4.0%	$386.62 +62.2%	-46.9%	$31.90B	$3.71B	44.32	2,770	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BMRN) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioMarin Pharmaceutical (BMRN) Competitors

BMRN vs. NTRA, RVMD, BIIB, ALNY, and BNTX

How does BioMarin Pharmaceutical compare to Natera?

Summary

How does BioMarin Pharmaceutical compare to Revolution Medicines?

Summary

How does BioMarin Pharmaceutical compare to Biogen?

Summary

How does BioMarin Pharmaceutical compare to Alnylam Pharmaceuticals?

Summary

How does BioMarin Pharmaceutical compare to BioNTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRN vs. The Competition

BioMarin Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioMarin Pharmaceutical (BMRN) Competitors

BMRN vs. NTRA, RVMD, BIIB, ALNY, and BNTX

How does BioMarin Pharmaceutical compare to Natera?

Which has stronger valuation & earnings, BMRN or NTRA?

Do insiders and institutionals hold more shares of BMRN or NTRA?

Does the media favor BMRN or NTRA?

Do analysts recommend BMRN or NTRA?

Which has more risk and volatility, BMRN or NTRA?

Is BMRN or NTRA more profitable?

Summary

How does BioMarin Pharmaceutical compare to Revolution Medicines?

Do analysts prefer BMRN or RVMD?

Which has stronger earnings & valuation, BMRN or RVMD?

Which has more volatility & risk, BMRN or RVMD?

Does the media favor BMRN or RVMD?

Do institutionals & insiders believe in BMRN or RVMD?

Is BMRN or RVMD more profitable?

Summary

How does BioMarin Pharmaceutical compare to Biogen?

Do analysts recommend BIIB or BMRN?

Which has higher earnings & valuation, BIIB or BMRN?

Does the media prefer BIIB or BMRN?

Do institutionals & insiders believe in BIIB or BMRN?

Is BIIB or BMRN more profitable?

Which has more risk and volatility, BIIB or BMRN?

Summary

How does BioMarin Pharmaceutical compare to Alnylam Pharmaceuticals?

Which has stronger earnings & valuation, BMRN or ALNY?

Do institutionals and insiders have more ownership in BMRN or ALNY?

Is BMRN or ALNY more profitable?

Do analysts prefer BMRN or ALNY?

Which has more risk & volatility, BMRN or ALNY?

Does the media favor BMRN or ALNY?

Summary

How does BioMarin Pharmaceutical compare to BioNTech?

Which has preferable valuation & earnings, BMRN or BNTX?

Which has more risk & volatility, BMRN or BNTX?

Is BMRN or BNTX more profitable?

Do institutionals and insiders have more ownership in BMRN or BNTX?

Does the media prefer BMRN or BNTX?

Do analysts prefer BMRN or BNTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRN vs. The Competition

BioMarin Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools